Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Julio Pow-Sang on Options for Low-and Intermediate-Risk Prostate Cancer

Julio Pow-Sang, MD
Published: Tuesday, Aug 30, 2016


Julio Pow-Sang, MD, chair of Urological Oncology at Moffitt Cancer Center, discusses the grey zone between low and intermediate risk in prostate cancer.
 
There is an overlap between low and intermediate-risk classification. At present, one of the main options for low-risk patients is to do active surveillance, says Pow-Sang.
 
Testing to determine low-risk was very rudimentary, he says. There was an approximately 30% chance that, with further testing, the patient was actually determined to be intermediate-risk. That was significant because intermediate-risk patients are recommended treatment, while low-risk patients are recommended active surveillance.

Newer tests and a better understanding of the behavior of the cancer have helped determine who those men are versus the ones who might need treatment, says Pow-Sang.
 

Julio Pow-Sang, MD, chair of Urological Oncology at Moffitt Cancer Center, discusses the grey zone between low and intermediate risk in prostate cancer.
 
There is an overlap between low and intermediate-risk classification. At present, one of the main options for low-risk patients is to do active surveillance, says Pow-Sang.
 
Testing to determine low-risk was very rudimentary, he says. There was an approximately 30% chance that, with further testing, the patient was actually determined to be intermediate-risk. That was significant because intermediate-risk patients are recommended treatment, while low-risk patients are recommended active surveillance.

Newer tests and a better understanding of the behavior of the cancer have helped determine who those men are versus the ones who might need treatment, says Pow-Sang.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x